Imagion Rights Issue Oversubscribed Raising $3 Million
Released
Released
Announcement PDF
®
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
23 April 2020
Imagion Rights Issue Oversubscribed Raising $3 Million
•
•
•
IBX Rights Issue and shortfall placement of $2.05 million was oversubscribed
Significant support from shareholders and new institutional investors
Follow-On Placement to raise an additional $0.96 million from excess demand
MELBOURNE - Imagion Biosystems Limited (ASX: IBX) (the Company) a company dedicated to improving
healthcare through the earlier detection of cancer, is pleased to advise that the Renounceable Rights Issue
announced on 25 March 2020 ("Offer") has closed oversubscribed and raised $2.05 million. To
accommodate some of the excess demand, the Company has agreed to raise an additional $0.96 million on
the same terms as the Offer ("Follow-On Placement").
The total amount raised is $3,009,790 (before costs) through the issue of 300,978,944 new fully paid ordinary
shares (Shares) and 300,978,944 new options, exercisable at 3 cents and expiring 28 April 2023. The new
options will be listed under the ASX code IBXOA. 96,466,065 Shares and 75,051,065 new options will be
issued in the Follow-On Placement using the Company's existing capacity under Listing Rule 7.1 and the
temporary extra placement capacity, not requiring additional shareholder approval. The issue of 27,415,000
new options in the Follow-On Placement will be subject to shareholder approval.
The final allocations are set out below.
Rights Issue
Follow-On Placement
Total
Funds raised
Shares
Options
$2,045,129
$964,661
$3,009,790
204,512,879
96,466,065
300,978,944
204,512,879
96,466,065
300,978,944
Mahe Capital Pty Ltd advised Imagion on the Rights Issue and Placement and acted as Lead Manager and
Underwriter of the Renounceable Rights Issue and Follow-On Placement. Imagion would like to thank all its
shareholders for their support and welcomes the new shareholders introduced to the register by Mahe
Capital.
The new securities are expected to be issued on Tuesday, 28 April 2020, in accordance with the timetable
in the Prospectus.
“We are very pleased to see shareholders supported the strengthening of our balance sheet,” said Bob
Proulx, Executive Chairman. “Combined with our recent tax refund, we are now in a much better position
to keep pressing forward with our plans for our first clinical testing of our MagSense™ nanoparticle
technology.”
This Announcement has been approved by the Board of Imagion Biosystems Limited
-ENDS
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystem.com
®
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases
earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian
Securities Exchange (ASX) in June 2017.
For further information please visit www.imagionbiosystems.com
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Australian Media & Investor Relations:
Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61-3-9866-4722
Imagion Biosystems Limited
ACN 616 305 027
Level 25, 525 Collins Street, Melbourne VIC 3000
www.imagionbiosystem.com
Share your feedback
Discover